- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04020367
Validation of a Process for the Manufacture of Stem Cells Isolated From the Nasal Cavity for Innovative Cell Therapy of Traumatized Peripheral Nerves (NOSE)
Despite progress in the time taken to take charge and in the quality of the surgical technique, the repair of damaged peripheral nerves has not improved in the last twenty years. Faced with these limitations of surgical treatment, multidisciplinary teams from Marseille and Rouen have come together to propose an innovative approach to cell therapy that can limit inflammation and improve axonal growth.
Cell transplantation now appears as an alternative to treat nerve damage. Scientific advances have shown in animal models as well as in humans that mesenchymal stem cells are good cellular candidates for supporting nerve regeneration after transplantation. On the other hand, their collection requires an invasive sample most often of bone marrow. A new stem cell candidate capable of stimulating nerve regeneration has recently been identified in the olfactory mucosa located in the nasal cavity. These cells are part of the "ecto-mesenchymal" stem cell family. They have biological characteristics very similar to those of mesenchymal stem cells of the bone marrow.
They exhibit high mitogenic activity and have a high potential for differentiation towards neural lineages. Given their properties and ease of access within the nasal cavity, ecto-mesenchymal stem cells offer new perspectives for cell therapy targeting nerve damage.
In this context, nasal ecto-mesenchymal stem cells represent an interesting reconstruction alternative, particularly in the indication of peripheral nerve lesions. They are directly and easily accessible to any individual. We therefore propose in this study to validate a method of manufacturing isolated stem cells from a biopsy of a few cubic millimeters of the nasal cavity of adults, taken during a surgical procedure, with a view to proposing shortly an innovative cell therapy. From each nasal biopsy taken, the cells will be amplified in vitro under pharmaceutical grade conditions and then controlled, validated and characterized in particular for their ability to differentiate into neural cells and for their lack of genetic instability. The cells will also be cryo-preserved and then thawed under pharmaceutical grade conditions in order to validate the maintenance of their quality after cryopreservation allowing to propose a delayed implantation according to the clinical context. This study requires the taking of 25 biopsies of nasal mucosa taken from adults to document the reproducibility of the manufacturing process and possible inter-donor variations. This validation data is an essential step before considering a clinical trial of Innovative Cell Therapy Drugs.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Patrick DESSI
- Phone Number: 33(0)4 91 43 55 20
- Email: patrick.dessi@ap-hm.fr
Study Locations
-
-
-
Marseille, France, 13354
- Recruiting
- Service d'Oto-Rhino-Laryngologie - Conception - AP-HM
-
Contact:
- Patrick DESSI
- Phone Number: 33(0)4 91 43 55 20
- Email: patrick.dessi@ap-hm.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Major adults men or women
- Affiliated to a social security scheme.
- Absence of contraindication to general and / or local anesthesia
- Relevant to an operative indication of functional surgery of the nose (septoplasty and / or turbinoplasty)
Exclusion Criteria:
- Patients with proven organic pathologies of the nervous system
- Pregnant and / or lactating women
- Persons deprived of their liberty
- Major under guardianship
- persons unable to read the information document.
- Patients with chronic inflammatory and / or infectious rhinosinusitis
- Patient under antithrombotic therapy
- Patient with hypersensitivity to local amide-bound anesthetics (such as lidocaine) or to any of the components, including methyl parahydroxybenzoate contained in the vehicle.
- Patient with porphyria.
- Patient with epilepsy not controlled by treatment.
- Patient with a history of surgery on the ethmoid and / or the average turbinate bilaterally.
- Patient with a history of cervico-cephalic radiotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: patients with biopsy
|
intervention under general or local anesthesia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
absence of caryotipic abnormalities during their amplification
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2018-40
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Septoplasty
-
King Abdulaziz Medical CityCompleted
-
Smith & Nephew, Inc.Completed
-
Assiut UniversityUnknownEndoscopic Septoplasty
-
Cairo UniversityUnknownIntranasal Dexmedetomidine | Intranasal Bupivacaine | Septoplasty SurgeriesEgypt
-
Baskent UniversityUnknownSeptum Deviated | Septoplasty/SeptorhinoplastyTurkey
-
The University of Texas Health Science Center,...CompletedPain Control After Functional Endoscopic Sinus Surgery and SeptoplastyUnited States
Clinical Trials on biopsy of mucosa's olfactory
-
Institut PasteurHopital LariboisièreRecruitingSARS-CoV-2 Acute Respiratory DiseaseFrance
-
University Hospital, BonnCompletedPost-traumatic Stress DisorderGermany
-
University Hospital, Strasbourg, FranceCompletedChronic Rhinosinusitis | Post-viral Anosmia | Post-traumatic Anosmia | Idiopathic Anosmia | Age-related Loss of SmellFrance
-
University of GiessenUniversity of Kiel; Masaryk UniversityRecruitingDysgeusia | Olfactory Disorder | Oral ComplicationGermany
-
University of LeipzigHelmholtz Institut für Metabolismus-, Adipositas- und Gefäßforschung; Klinik... and other collaboratorsRecruiting
-
Central Hospital, Nancy, FranceCompletedEthmoid Sinus AdenocarcinomaFrance
-
Université de Reims Champagne-ArdenneNot yet recruiting
-
NRG OncologyNational Cancer Institute (NCI)SuspendedStage II Breast Cancer | Stage IIIA Breast Cancer | Invasive Breast Carcinoma | Stage IIA Breast Cancer | Stage IIB Breast CancerUnited States, Canada
-
University College, LondonNIHR UCLH BRC; The Bernice Bibby Research TrustCompletedRare Diseases | Siderosis | Presbycusis | Neurological Disorder | Age Related Hearing LossUnited Kingdom
-
Jonsson Comprehensive Cancer CenterWithdrawnStage III Prostate AdenocarcinomaUnited States